论文部分内容阅读
近几年来,随着我国市场的开放,国外一些大的制药公司纷纷进入中国,基因工程药物也随之进入我国市场,并在我国药品市场中占有相当的份额。美国Amgen公司生产和销售的EPO、G-CSF遍布我国许多大医院,售价高达2000元人民币/支。这对我国生物制药工业是一个严竣的挑战。因此,我们必须迎头赶上,加快基因工程药物的开发,迅速推进我国基因工程药物产业化的进程。 据此,我国863计划生物技术领域在“八五”和“九五”两个五年计划中都把基因工程药物的开发做为我国生物高技术产业化的突破口,并在本世纪末达到下述目标: 1.有15种以上高技术药物投入市场,为防治我国常见病、多发病,提高人民健康保障做出贡献; 2.在“863”计划引导下建立的生物制药产业,年产值达10～20亿元; 3.为形成我国高技术药物产业奠定基础; 4.为改造我国大中型制药企业做出贡献。
In recent years, with the opening of China’s market, some large foreign pharmaceutical companies have entered China, genetic engineering drugs have also entered the Chinese market, and occupy a considerable share of the pharmaceutical market in China. The EPO and G-CSF produced and sold by American Amgen Company are found in many large hospitals in China and are priced as high as RMB 2,000 per unit. This is a tough challenge for China’s biopharmaceutical industry. Therefore, we must catch up, speed up the development of genetically engineered drugs, and quickly advance the process of industrialization of genetic engineering drugs in China. Accordingly, in the two-year plan of the “863” and “Ninth Five-Year Plan” of China’s 863 Program, the development of genetic engineering drugs has become the breakthrough point of China’s bio-tech industrialization and reached the following in the end of this century. Objectives: 1. More than 15 kinds of high-tech drugs have been put into the market to contribute to the prevention and treatment of common diseases and frequent diseases in China, and to improve people’s health protection; 2. The biopharmaceutical industry established under the guidance of the “863” Plan has an annual output value of 10 ~ 2 billion yuan; 3. To lay a foundation for the formation of China’s high-tech pharmaceutical industry; 4. To make contributions to the transformation of China’s large and medium-sized pharmaceutical companies.